Aarti Pharmalabs LimitedQ1 FY27 Results & Financial Update
Aarti Pharmalabs Limited: Q1 FY27 consolidated results and company financials – revenue ₹535.80 Cr, PAT ₹76.14 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Aarti Pharmalabs price & chart
Market price₹885.90
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Aarti Pharmalabs Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the quarter ended June 30, 2026 (Q1 FY27), Aarti Pharmalabs reported consolidated revenue from operations of INR 535.80 crore on a total income of INR 536.25 crore.
Profit before tax (PBT) for the quarter stood at INR 93.65 crore, while profit after tax (PAT) settled at INR 76.14 crore, resulting in a PAT margin of approximately 14.21%.
Basic earnings per share (EPS) for the period was recorded at INR 8.39 based on the reported consolidated net profit.
The financial results reflect steady operational performance during the quarter under review, supported by underlying business activities across its manufacturing units.
Finance costs for the quarter were reported at INR 12.88 crore, reflecting debt servicing obligations associated with the company's capital structure and operational funding.
Depreciation and amortization expenses stood at INR 30.03 crore, capturing the systematic wear and tear of the company's manufacturing plants and fixed asset base.
Tax expenses for the quarter were recorded at INR 24.92 crore, representing the statutory provisions applied to the period's taxable earnings.
Aarti Pharmalabs Limited reported its consolidated financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, showcasing total consolidated revenue from operations of INR 535.80 crore.
01 · Business model
What does Aarti Pharmalabs do?
Aarti Pharmalabs Limited operates in the pharmaceuticals sector, focusing on the development, manufacture, and commercialization of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals.
The company's operational model relies on advanced chemical synthesis capabilities, process optimization, and regulatory-compliant manufacturing facilities serving global pharmaceutical markets.
Revenue generation is driven by commercial supply contracts for complex APIs and regulated intermediates sold to domestic and international pharmaceutical formulators.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹535.80 Cr |
| Total income | ₹536.25 Cr |
| Profit before tax | ₹93.65 Cr |
| Profit after tax | ₹76.14 Cr |
| EPS | ₹8.39 |
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Reported consolidated revenue from operations reached INR 535.80 crore for Q1 FY27, underpinned by core pharmaceutical manufacturing and product sales.
Generated INR 0.45 crore in other income during the quarter, contributing marginally to the total income of INR 536.25 crore.
Revenue from operations reached INR 535.80 crore for Q1 FY27, driven by active pharmaceutical ingredient and intermediate supplies.
Non-operating items contributed an additional INR 0.45 crore, bringing total consolidated income to INR 536.25 crore.
Revenue from operations reached INR 535.80 crore during the quarter ended 30 June 2026, supported by active pharmaceutical ingredients and intermediate sales.
What drove margins
Achieved a PAT margin of 14.21% for the quarter, calculated from a PAT of INR 76.14 crore on total operating revenue.
Depreciation and amortization charges of INR 30.03 crore reflect the capital-intensive nature of chemical and pharmaceutical manufacturing assets.
Finance expenses of INR 12.88 crore impacted profitability, representing borrowing costs incurred during the period.
Depreciation and amortisation expenses of INR 30.03 crore reflect the capital-intensive nature of the manufacturing facilities.
Interest and finance charges amounted to INR 12.88 crore for the quarter.
The company achieved a net profit after tax of INR 76.14 crore on total income of INR 536.25 crore, resulting in a reported PAT margin of approximately 14.21%.
Depreciation and amortization expenses stood at INR 30.03 crore, while finance costs were recorded at INR 12.88 crore for the quarter.
04 · Reported developments
What changed operationally
The company sustained solid profitability with a net profit of INR 76.14 crore and basic EPS of INR 8.39 for the quarter ended June 30, 2026.
05 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
Incurred finance costs of INR 12.88 crore during the quarter for debt servicing and financing requirements.
06 · Key Q&A
The quarter, answered directly
What does Aarti Pharmalabs do?
Aarti Pharmalabs Limited operates in the pharmaceuticals sector, focusing on the development, manufacture, and commercialization of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals.
What is the clearest takeaway from Q1 FY27?
For the quarter ended June 30, 2026 (Q1 FY27), Aarti Pharmalabs reported consolidated revenue from operations of INR 535.80 crore on a total income of INR 536.25 crore.
What drove revenue or demand?
Reported consolidated revenue from operations reached INR 535.80 crore for Q1 FY27, underpinned by core pharmaceutical manufacturing and product sales.
What mattered most for margins or profitability?
Achieved a PAT margin of 14.21% for the quarter, calculated from a PAT of INR 76.14 crore on total operating revenue.
What should the next disclosure help confirm?
Monitor upcoming quarterly financial filings for sequential trends in revenue, cost structures, and profitability margins.
07 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
08 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Financial Disclosures: Monitor upcoming quarterly financial filings for sequential trends in revenue, cost structures, and profitability margins.
- 02
Capital Expenditure Progress: Track updates regarding plant capacity utilization and the commissioning status of ongoing or planned capital projects.
- 03
Subsequent Quarterly Filings: Monitor upcoming quarterly disclosures to track revenue trends, margin trajectory, and debt servicing metrics.
- 04
Subsequent Quarterly Performance: Monitor upcoming financial disclosures for comparative performance and sequential operating trends.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.